Quality Control of Antibody Responses by the Innate Signaling Adaptor MAVS
通过先天信号转导适配器 MAVS 进行抗体反应的质量控制
基本信息
- 批准号:9978499
- 负责人:
- 金额:$ 23.03万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-03-01 至 2022-02-28
- 项目状态:已结题
- 来源:
- 关键词:AddressAdvanced DevelopmentAntibody AffinityAntibody FormationAntibody ResponseAntigensAttenuated VaccinesB-LymphocytesCD4 Positive T LymphocytesCD8-Positive T-LymphocytesCellsCessation of lifeCytosolDefectDevelopmentDiseaseEpitopesExpression ProfilingFamilyFlavivirusFoundationsFutureGene ExpressionGenerationsGenesGoalsHumanHumoral ImmunitiesImmuneImmune responseImmune systemImmunityImpairmentIndividualInfectionInflammatoryInnate Immune ResponseInterferonsInvestigationKnowledgeMediator of activation proteinMembraneMicrobeMitochondriaModelingMolecularMusMyeloid CellsNatural ImmunityNeurologicPattern recognition receptorQuality ControlRNARNA HelicaseRNA VirusesRecoveryRegulationRegulatory T-LymphocyteRoleSignal PathwaySignal TransductionStructure of germinal center of lymph nodeSubunit VaccinesSymptomsTestingToll-like receptorsVaccine DesignVaccinesViralVirusVirus DiseasesWest Nile viral infectionWest Nile virusWorkadaptive immune responseadaptive immunitybasecytokinedesignfluinsightmicrobialmortalitymosquito-bornemutantneutralizing antibodynovel vaccinespathogenperoxisomereceptorresponsetooltransmission process
项目摘要
ABSTRACT
Innate immune recognition of microbial compounds by pattern recognition receptors (PRRs) represents a
central regulatory checkpoint in the control of adaptive immune responses. Rig-I-like receptors (RLRs) comprise
a PRR family that includes the RNA helicases RIG-I and MDA-5. RLRs recognize microbial RNA species in the
cytosol and rely on the essential signaling adaptor MAVS for the induction of the cellular response. RLRs are
important mediators of innate immunity to multiple viral infections. However, the role of RLRs in the regulation of
adaptive immunity is still poorly understood. MAVS-deficient mice infected with West Nile Virus (WNV) fail to
develop an effective virus-specific neutralizing antibody response, suggesting an important role for MAVS
signaling in the control of humoral immunity. Here, we will employ a single-round-of-infection mutant of WNV to
probe the central hypothesis that RLRs regulate the quality control of the antibody response. Our study will
therefore address fundamental mechanistic questions about the role of RLRs in the adaptive immune response
to WNV and other RNA viruses. Such insights will advance the development of novel vaccine strategies against
WNV and related flaviviruses.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DOMINIK SCHENTEN其他文献
DOMINIK SCHENTEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
- 批准号:
10935820 - 财政年份:2023
- 资助金额:
$ 23.03万 - 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
- 批准号:
10932514 - 财政年份:2023
- 资助金额:
$ 23.03万 - 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
- 批准号:
10704845 - 财政年份:2023
- 资助金额:
$ 23.03万 - 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
- 批准号:
10709085 - 财政年份:2023
- 资助金额:
$ 23.03万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10409385 - 财政年份:2022
- 资助金额:
$ 23.03万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10710595 - 财政年份:2022
- 资助金额:
$ 23.03万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10630975 - 财政年份:2022
- 资助金额:
$ 23.03万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
- 批准号:
10710588 - 财政年份:2022
- 资助金额:
$ 23.03万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10788051 - 财政年份:2022
- 资助金额:
$ 23.03万 - 项目类别: